MPDL3280A

April 12, 2016April 12, 2016

Genentech’s Immunotherapy Drug Atezolizumab Granted FDA Priority Review for Treatment of NSCLC

News

Genentech announced that its Biologics License Application (BLA) for atezolizumab was granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic ... Read more

March 16, 2016March 16, 2016

Genentech’s Advanced Bladder Cancer Drug Atezolizumab Granted FDA Priority Review

News

Genentech recently announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) and has granted Priority Review for atezolizumab for the treatment of patients ... Read more

May 22, 2015May 22, 2015

Experimental Therapeutic Combination Found to Induce High Response Rate in Advanced Lung Cancer Patients

News

A team of researchers from several institutes and universities in the United States will disclose promising early results on the combination of an anti-cancer agent (MPDL3280A) and standard chemotherapy for ... Read more

May 18, 2015May 18, 2015

Genentech Fostering Anti-PDL1 Immunotherapy in Lung Cancer

News

Genentech will present the most recent results on their ongoing developments for non-small cell lung cancer (NSCLC) at this years’ Annual Meeting of the American Society of Clinical Oncology (ASCO). ... Read more

May 12, 2015May 12, 2015

Novel Genentech Medicines for Cancer Treatment Presented at ASCO Meeting

News

During the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from 29 May to 2 June, Genentech will present the latest results on ten of its approved cancer and other ongoing ... Read more

December 8, 2014December 8, 2014

Tailoring Cancer Treatment with PD-L1 Biomarkers

News

The laboratory of F. Stephen Hodi, MD of Dana-Farber, discovered a possible reason for the less than hoped clinical response of cancer patients involved in a recent trial for MPDL3280A, ... Read more

August 26, 2014August 26, 2014

PD-L1 (SP142) Antibody Developed By Spring Bioscience To Be Studied As Cancer Immunotherapy

News

A new PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody developed as a part of Roche/Genentech’s anti-PD-L1 (MPDL3280A) immunotherapy program has been released commercially by Spring Bioscience (Spring), a member of ... Read more